PDE4 cAMP phosphodiesterases are widely expressed enzymes that serve as major regulators of cAMP signalling in cells. They provide targets for therapeutics having anti-inflammatory and cognitive-enhancing properties. ERK2 (extracellular-signal-regulated kinase 2) interacts with the PDE4 catalytic unit by binding to a KIM (kinase interaction motif) docking site located on an exposed β-hairpin loop and an FQF (Phe-Gln-Phe) specificity site located on an exposed α-helix. These flank a site that allows phosphorylation by ERK, the functional outcome of which is orchestrated by the N-terminal UCR1/2 (upstream conserved region 1 and 2) modules. The three classes of PDE4 isoforms differ in these regulatory modules, allowing phosphorylation by ERK to lead to either inhibition or activation. ERK inhibition of long isoforms is regulated by a unique feedback control whereby elevated cAMP levels cause PKA (protein kinase A) to phosphorylate UCR1 and ablate the inhibitory action of ERK. PDE4 isoforms can also be found in complex with β-arrestins where they provide a novel part of the cellular desensitization mechanism to receptor-mediated cAMP signalling. Stimulation of the β 2 -adrenoceptor recruits β-arrestins with bound PDE4, delivering an enzyme capable of degrading cAMP at its site of synthesis at the plasma membrane. Use of dominant negative PDE4 isoforms identifies that a major role of recruited PDE4 is to regulate plasma membrane PKA activity involved in phosphorylating the β 2 -adrenoceptor. Recruited PDE4 thus desensitizes the ability of the β 2 -adrenoceptor to activate ERK via G i .
Signalling cross-talk
The functioning of all cells is regulated by the complex interactions achieved by and between a myriad of cell signalling pathways. None of these individual pathways operate in isolation. Rather, they integrate and interact with other signalling pathways in order to achieve an integrated response. Along with the identification of such interacting networks there has arisen the realization that integration is achieved not only temporally, but also spatially. This latter concept has been strengthened due to the appreciation that many 'signalling proteins' contain either modules or motifs that confer targeting to spatially distinct sites in cells. This allows signalling processes to be compartmentalized. Cell signalling is thus not achieved by a homogeneous dispersal of components and signals throughout the cell interior but by the channelling of signals through defined pathways in order to control defined sets of processes.
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ERK (extracellular-signal-regulated kinase) and cAMP signalling interactions
The cAMP [1] and ERK mitogen-activated protein kinase [2, 3] pathways play pivotal roles in controlling a wide range of responses in different cell types. It is now appreciated that cross-talk between these pathways occurs at a number of distinct points and that these effects can be tailored in a celltype-specific fashion by the selective expression of specific isoforms of enzymes positioned at critical control points so as to mediate cross-talk regulation [4] . The identification of cross-talk in the ERK/cAMP signalling pathways originated in studies done on the protein kinase, Raf (Figure 1 ). The cell-type-specific expression of Raf-1 and B-Raf isoforms allows elevated cAMP levels to couple either negatively or positively to the activation of ERK. This is because inhibition of Raf-1 functioning can be achieved through its phosphorylation by PKA (protein kinase A). Conversely, elevated cAMP levels lead to the activation of B-Raf and hence to ERK activation. The precise mechanism for such actions remains to be elucidated, although it is considered to occur through activation of the monomeric G-protein, Rap1. There is evidence to suggest that Rap1 activation may occur independently of PKA. This was originally suggested [5] as being achieved upon the binding of cAMP to EPAC (exchange proteins activated by cAMP), which serve as cAMPGEFs (GTP exchange factors). These interact with Rap1 to facilitate GDP-GTP exchange and concomitant activation of Rap1. However, recent studies done with a novel EPAC agonist point to this process as being unlikely [6] . While there is evidence that PKA may phosphorylate Rap1 and activate it, at least in certain cells, this does not explain how inhibitors of PKA do not, seemingly, prevent B-Raf activation of ERK in other cells. Thus key questions regarding cAMP activation of the ERK pathway remain to be elucidated. Interestingly, however, another point of cross-talk has been shown in cells that express PTPs (protein tyrosine phosphatases) [7] , which are able to dephosphorylate and thus de-activate ERK. It has been shown [7] that for PTP to achieve this action it has to interact with ERK using not only its active site but also a distinct docking site [KIM (kinase interaction motif); see below]. Within this docking site on ERK2 is a serine residue, which can be phosphorylated by PKA, whereupon docking to ERK is ablated. Uncoupling PTP from ERK thus attenuates dephosphorylation and in so doing provides a means for elevated cAMP levels to increase the levels of active phosphorylated ERK in a cAMPand PKA-dependent fashion ( Figure 1 ).
cAMP PDEs (phosphodiesterases)
cAMP is generated at the cytosolic surface of the plasma membrane by the action of adenylate cyclases for which a large family of genes generates distinct isoforms [8] [9] [10] . These can be activated by certain G-protein-coupled receptors that are able to interact with G s . However, the only means of degrading cAMP is through the action of various cyclic nucleotide PDEs. A large number of genes coupled with alternative mRNA splicing generate a very large family of PDE isoenzymes with distinct kinetic, regulatory and targeting properties [1, [11] [12] [13] [14] [15] . Of these, the PDE4 multi-gene family [4, 12, 14, 15] has attracted considerable interest, as inhibitors selective for these enzymes have potential therapeutic use for treating various inflammatory diseases, such as asthma and chronic obstructive pulmonary disease, as well as serving as cognitive enhancers and anti-depressants [16] [17] [18] [19] [20] [21] [22] . Four genes (PDE4A-PDE4D) encode over 18 different PDE4 isoforms [15] . Such multiplicity is achieved through the use of distinct promoters coupled to alternative mRNA splicing. Each PDE4 isoform is characterized by a unique N-terminal region encoded by 5 exons. These are then further sub-categorized into long, short and super-short isoforms (Figure 2 ). The long isoforms have two regulatory modules, called UCR1 (upstream conserved region 1) and UCR2, which are located between their unique N-terminal regions and the catalytic unit. The short isoforms have only UCR2, whereas the supershort isoforms possess a truncated UCR2. The UCR modules can interact together in long forms [23] and provide the regulatory input for stimulatory phosphorylation by PKA, which occurs on a single serine residue located in UCR1 [24] [25] [26] [27] .
The PDE4 family is uniquely engineered for regulation by ERK-mediated phosphorylation
The catalytic unit of the PDE4B, PDE4C and PDE4D, but not the PDE4A, families contains a single consensus site for phosphorylation by ERK, which in the PDE4D3 isoform is Ser-579 [28] [29] [30] [31] [32] . This lies in the consensus motif ProXaa-Ser-Pro and, certainly, recombinant active ERK can phosphorylate recombinant PDE4D3 at a single site, Ser-579 [29] . However, having a consensus site and being phosphorylated in vitro can be far removed from phosphorylation in vivo. Work on transcription factors that are phosphorylated and regulated by ERK and JNK (c-Jun N-terminal protein kinase) has led to the discovery of both docking and specificity motifs, which designate specific transcription factors as authentic in vivo substrates for these kinases [33] . Of these, the KIM motif (Val-Xaa-Xaa-Lys-Lys-Xaa 6 -Leu-Leu-Leu-Xaa 122 -phosphoSer) serves as a docking site on protein targets for both ERK and JNK and is located N-terminal to the target serine site. Specificity for ERK, rather than JNK, is conferred by the FQF motif (where FQF is Phe-Gln-Phe in one-letter code), located C-terminal to the target serine-phosphorylation site (phosphoSer-Xaa 18 -Phe-Gln-Phe). PDE4 enzymes have exquisitely conserved KIM and FQF sites that straddle the serine target for phosphorylation by ERK [32] . Indeed, knowledge of the three-dimensional structure of PDE4B/D enzymes [34, 35] shows [15] that all of these three key sites for ERK action are located on a single sub-domain of the PDE4 catalytic unit, with the KIM site being found on an exposed β-hairpin loop and the FQF site on an exposed α-helix. They are thus excellently displayed for interaction with ERK. Indeed, PDE4D3 can be co-immunoprecipitated with ERK in a process ablated by mutation of either the KIM or the FQF motif [32] . Not only this, but ERK can phosphorylate PDE4D, B and C but not PDE4A isoforms, which lack the consensus site for ERK phosphorylation, in intact cells [32] .
The effect of phosphorylation by ERK of PDE4 long isoforms is to cause their inhibition, by around 80% [28] [29] [30] 32] . This can be mimicked by mutation, to Asp, of the target Ser in recombinant long form enzymes. Interestingly, ERK phosphorylation of PDE4 long forms can provide a novel feedback regulatory system [29] . Thus ERK inhibition of PDE4 long forms can cause a rise in cAMP, whereby the consequential activation of PKA now feeds back to phosphorylate the PDE4 long form, so as to overcome its inhibition by ERK. The net effect of this is that ERK activation of PDE4 long forms can generate a transient increase in cAMP levels. This is clearly evident in epidermal growth factor-challenged cells where PDE4 long forms provide the dominant activity. However, as many, if not all, PDE4 isoforms are targeted to specific sites in cells [14, 15] , then in vivo one might expect to see such transient effects constrained to spatially discrete sites within cells. Indeed, this may well occur for the PDE4D3 long isoform, which can be anchored to AKAPs (PKA-anchoring proteins) in certain cells [36, 37] , thus providing a uniquely sited regulatory system. Interestingly, however, ERK phosphorylation of a recombinant 'naked' PDE4D catalytic unit, free of UCR1/2, has little effect on its catalytic activity [32] . Indeed, it appears that it is the interacting UCR1/2 units that orchestrate the functional outcome of ERK phosphorylation of the PDE4 catalytic unit to yield a profound inhibitory response. Similarly, UCR1 inputs the effect of PKA-mediated phosphorylation [26, 27] , which both activates PDE4 long forms and negates the inhibitory effect of ERK phosphorylation [28, 29] . Indeed, it has been shown that PKA phosphorylation changes (reduces) the interaction between UCR1 and UCR2 [23] . It is then intriguing to find that ERK phosphorylation of the catalytic unit in PDE4 short forms is reprogrammed, by the naked UCR2, to cause activation [28, 32] . Thus as with the diametrically opposed regulatory effects that elevated cAMP levels exert on ERK signalling through the Raf-1 and B-Raf isoforms, here we have identified the corollary to this system. The activation of ERK acts on PDE4 enzymes to regulate cAMP signalling either negatively or positively depending upon the expression pattern and localization of PDE4 long and short isoforms. Additionally, the super-short isoforms, which have a naked but truncated UCR2, show little response to ERK phosphorylation except for a small inhibitory effect that is insensitive to reversal by elevated cAMP levels as it contains no target for PKA action [28, 32] .
Thus PDE4B, C and D isoforms appear to be uniquely designed to respond to regulation by ERK via their consensus phosphorylation site spanned by docking and specificity sites in the catalytic unit, coupled to the UCR1/2 regulatory modules.
That PKA activation can negate the inhibitory effect of ERK phosphorylation on PDE4 long isoforms offers a means of re-programming ERK action on these enzymes in certain cells [30] . This has been seen, for example, in smooth muscle cells, where growth factor activation of ERK causes the rapid activation of PKA through an autocrine system, which leads to a net activation of PDE4D long forms in these cells rather than any inhibition [30] . This is an interesting special case as, at the same time as ERK is activated to phosphorylate PDE4D long forms, it also activates phospholipase A 2 in these cells. It is this this latter action that leads to the generation of prostaglandin E 2 via cyclo-oxygenase action, which activates adenylate cyclase in an autocrine fashion, leading to cAMP generation. The ensuing increase in cAMP causes PKA to phosphorylate the PDE4D long isoforms, thereby not only negating any inhibitory effect of ERK but yielding an ERK-mediated activation of these long PDE4D isoforms. The use of phospho-specific antisera allows ready tracking of these actions on PDE4D long forms, with pharmacological intervention uncovering the distinct pathways. Thus the inhibitory effect of ERK-mediated phosphorylation on PDE4D long isoforms in these cells can be unmasked by inhibiting PKA, phospholipase A 2 or cyclo-oxygenase 2. Intriguingly, ERK activation in smooth muscle cells has been shown to alter the stability of the mRNA for the super-short PDE4D1 isoform and has been suggested to elicit the intracellular re-distribution of the PDE4D3 long isoforms [38, 39] . These data exemplify the complexities involved in resolving regulation of PDE4 isoforms in different cell types and the range of possible connections available to cells, which is achieved by the selective expression of distinct isoforms in these component pathways.
Recruitment of a PDE4-β-arrestin complex controls ERK signalling via the β 2 AR (β 2 -adrenoceptor)
β-Agonist occupancy of the β 2 AR allows coupling to G s and the activation of adenylate cyclase [40] . It also allows Gprotein receptor kinases to phosphorylate it, recruiting the cytosolic protein β-arrestin, which sterically inhibits coupling of the β 2 AR to G s , causing desensitization [40] [41] [42] [43] . Additionally, PKA activation will phosphorylate the β 2 AR, not only to facilitate its uncoupling from G s , but also to switch coupling to G i and hence to the activation of ERK [42] .
Recently, it has been shown that PDE4 isoforms can interact with β-arrestin and thus be recruited to the β 2 AR in an agonist-dependent fashion [44, 45] . This delivers active PDE4 to the site of cAMP synthesis. The PDE4 catalytic site appears to provide an anchor site for β-arrestin, indicating that all PDE4 isoforms have the potential to be so complexed and recruited. However, our recent studies [46] indicate that PDE4D5 is selectively recruited for interaction and that this is because it has an additional site for binding to β-arrestin, which is located within the unique N-terminal region of PDE4D5. The use of so-called dominant-negative PDE4 isoforms, rendered catalytically inactive by a point mutation in their active site, has allowed the functional consequences of PDE4 recruitment to be identified [44, 45] . It would appear that a key role for β-arrestin-recruited PDE4 is in controlling a specific pool of membrane-bound, anchored PKA that can elicit the phosphorylation of the β 2 AR itself [45] . Recruited PDE4 serves to attenuate the activity of plasma membrane PKA responsible for phosphorylating the β 2 AR, presumably by lowering local cAMP levels. Thus the recruited PDE4 serves to desensitize the switched coupling of the β 2 AR to activation of G i and hence to ERK [45] . The cell-type-specific expression of appropriate PDE4 isoforms can thus serve to regulate the switching of coupling of the β 2 AR from G s to G i .
Conclusion
PDE4 and Raf isoforms, as well as the PTPs, play a pivotal role in shaping the coupling between the cAMP and ERK signalling pathways. This can be determined in a cell-typespecific fashion by controlling the levels of expression of these various components to achieve positive, negative or null signals. That specific components can be localized at particular sites within cells offers the possibility for tailoring compartmentalized responses. Such sophistication requires new technologies aimed at assessing changes in the functioning of cAMP and ERK signalling in distinct cellular sub-compartments. It also offers the possibility of developing novel therapeutics aimed at disrupting the targeting of distinct components in cells.
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